Inanovate

Executive Summary

Inanovate, founded in 2015 and headquartered in San Diego, is a diagnostics company developing the Bio-ID platform, a technology designed to lower the cost and improve the accuracy of diagnostic tests by rapidly and precisely measuring multiple disease-related biomarkers from patient blood samples. The platform addresses the growing need for affordable, multiplexed testing in point-of-care and decentralized settings, aligning with trends toward precision medicine and early disease detection. Despite being private with limited public financial details, Inanovate's focus on multi-biomarker analysis positions it to compete in the expanding diagnostics market. The company's ability to achieve regulatory milestones and secure partnerships will be key to its adoption and commercial success.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) Clearance for Bio-ID Platform40% success
• Q4 2026Strategic Partnership with Diagnostic Laboratory50% success
• Q3 2026Series A Financing Round30% success